Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (NASDAQ: CDXS) generates news primarily around its enzymatic technologies for therapeutics manufacturing and the development of its ECO Synthesis® / ECO Synthesis™ manufacturing platform. The company’s announcements frequently highlight progress in applying enzyme-based processes to small molecule pharmaceuticals manufacturing and nucleic acid synthesis, as well as steps toward enabling scaled manufacture of RNAi therapeutics, including siRNA and other oligonucleotides, through enzymatic routes.
News about Codexis often covers financial results and business updates, where the company reports on revenues, product gross margins, research and development spending, and strategic priorities. These releases typically include commentary on the performance of its Pharma Biocatalysis business, the status of ECO Synthesis-related activities, and the company’s cash position and funding plans as disclosed in its quarterly and annual reporting cycles.
Another recurring theme in Codexis news is collaborations and evaluation agreements with organizations involved in oligonucleotide therapeutics. The company has announced agreements with CDMOs and CRDMOs such as Nitto Denko Avecia and Axolabs to evaluate the ECO Synthesis manufacturing platform for therapeutic siRNA and other oligonucleotides. These updates describe how partners assess Codexis’s enzymatic approach and indicate that such evaluations may lead to licensing discussions and broader adoption.
Codexis also issues news about infrastructure and strategic initiatives, including the signing of a lease for a GMP manufacturing facility in Hayward, California, intended to support GMP manufacturing of siRNA and other oligonucleotides using ECO Synthesis. Additional releases detail organizational changes, leadership transitions, workforce streamlining aligned with an enhanced focus on ECO Synthesis, and participation in industry conferences such as TIDES USA and TIDES Europe, where Codexis and its collaborators present data on enzymatic manufacturing technologies.
Investors and observers who follow CDXS news can use this stream of updates to monitor Codexis’s progress in advancing enzyme-based manufacturing platforms, its relationships with manufacturing partners, and its evolving strategic focus within therapeutics manufacturing.
Codexis (Nasdaq: CDXS) has launched an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of shares. The net proceeds will fund R&D, enhance infrastructure, and support the development of performance enzymes and biotherapeutics. Codexis may also invest in complementary businesses. Notably, Jefferies LLC, Cowen and Company, and Stifel are managing the offering. Market conditions may impact the completion and terms of this offering.
Codexis (NASDAQ: CDXS) and Casdin Capital have launched the SynBio Innovation Accelerator, aimed at funding early-stage companies in synthetic biology. This initiative will see Casdin planning to invest upwards of $50 million in the sector. The first investment is a $1.75 million stake in Arzeda, a computational protein design firm, where both companies will collaborate to enhance enzyme development using machine learning. John Nicols, CEO of Codexis, emphasized the transformative potential of synthetic biology, while Eli Casdin highlighted the accelerator's role in stimulating innovation.
Codexis, a leader in protein engineering, announced its participation in three virtual investment conferences. The events include the Stifel Healthcare Conference on November 16, 2020, at 3:20 p.m. ET, the 11th Annual Craig-Hallum Alpha Select Conference on November 17, 2020, and the Stephens Annual Investment Conference on November 18, 2020, at 1:00 p.m. ET. Presentations will be webcasted and available for replay on the company's investor website. Codexis utilizes its proprietary technology for developing proteins for pharmaceuticals and industrial applications.
Codexis, Inc. (Nasdaq: CDXS) reported total revenues of $18.4 million for Q3 2020, a drop from $21.9 million in Q3 2019. Product revenue was $8.4 million, down from $10.4 million year-over-year, largely due to demand timing. R&D revenue decreased to $10.0 million from $11.6 million, impacted by fewer milestone payments. Despite a net loss of $6.1 million, management expects 2020 revenue to exceed pre-COVID guidance, with robust growth across its segments, including Novel Biotherapeutics.
Codexis, a leader in protein engineering, is set to announce its third quarter 2020 financial results on November 5, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide company updates. Investors are encouraged to pre-register for the call to streamline access. The announcement underlines Codexis' focus on transparency and engagement with its investment community.
Codexis, a leading protein engineering company, announced its participation in two upcoming virtual investment conferences. The first event is the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 a.m. ET. The second is the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 8:00 a.m. ET. A live webcast and replay will be available on their Investors website.
Codexis, Inc. (NASDAQ: CDXS) will report its second quarter 2020 financial results on August 6, 2020, after the market closes. The management team will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company. Participants can pre-register for the call to receive a passcode for immediate access. A live webcast will also be available on the Codexis investor relations website, with an archive accessible for 90 days. For those unable to attend live, a replay will be available for 48 hours following the call.
Codexis (Nasdaq: CDXS) announces a partnership with Molecular Assemblies to enhance enzymatic DNA synthesis. Codexis will invest $1 million in Series A preferred stock and gain an expected ownership stake over 10% through performance milestones. This collaboration leverages Codexis' CodeEvolver® technology to improve DNA polymerase enzymes, facilitating cost-effective, high-quality DNA production across industries like pharmaceuticals and synthetic biology. Both companies aim to revolutionize DNA synthesis and enable innovations in biotherapeutics, diagnostics, and data storage solutions.
Codexis, Inc. (Nasdaq: CDXS) welcomed two new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS, Ph.D., during its 2020 Annual Meeting of Stockholders. This addition aims to enhance the company’s focus on biotherapeutics development. Dr. Moore brings extensive experience from Allogene Therapeutics and Amgen, while Dr. Dilly has a robust background in executive management at Sierra Oncology and Aimmune Therapeutics. Additionally, Dr. Patrick Yang was re-elected to the board. These changes align with Codexis's strategy to strengthen its leadership in the biotechnology sector.
Codexis (Nasdaq: CDXS) and Alphazyme have formed a Co-Marketing & Enzyme Supply Collaboration Agreement to produce and market enzymes for life science applications. The agreement will launch three key enzymes in 2020: a high-fidelity DNA polymerase, an evolved T7 RNA polymerase for mRNA therapeutics, and a reverse transcriptase for viral diagnostics. This collaboration aims to accelerate the market introduction of high-performing enzymes to address critical molecular biology challenges, especially in light of the COVID-19 pandemic.